Published in Gut on April 20, 2011
The chromatin regulator Brg1 suppresses formation of intraductal papillary mucinous neoplasm and pancreatic ductal adenocarcinoma. Nat Cell Biol (2014) 1.87
Proteomic mucin profiling for the identification of cystic precursors of pancreatic cancer. J Natl Cancer Inst (2014) 1.69
Brg1 promotes both tumor-suppressive and oncogenic activities at distinct stages of pancreatic cancer formation. Genes Dev (2015) 1.58
Prevalence, Diagnosis and Management of Pancreatic Cystic Neoplasms: Current Status and Future Directions. Gut Liver (2015) 0.97
Intraductal Papillary Mucinous Neoplasm of Pancreas. N Am J Med Sci (2015) 0.97
Early detection and prevention of pancreatic cancer: is it really possible today? World J Gastroenterol (2014) 0.95
IPMN involving the main pancreatic duct: biology, epidemiology, and long-term outcomes following resection. Ann Surg (2015) 0.95
GNAS sequencing identifies IPMN-specific mutations in a subgroup of diminutive pancreatic cysts referred to as "incipient IPMNs". Am J Surg Pathol (2014) 0.92
Intraductal papillary mucinous neoplasms of the pancreas--a surgical disease. Nat Rev Gastroenterol Hepatol (2012) 0.89
Precursor lesions for sporadic pancreatic cancer: PanIN, IPMN, and MCN. Biomed Res Int (2014) 0.88
Not all mixed-type intraductal papillary mucinous neoplasms behave like main-duct lesions: implications of minimal involvement of the main pancreatic duct. Surgery (2014) 0.87
Oncocytic-type intraductal papillary mucinous neoplasm (IPMN)-derived invasive oncocytic pancreatic carcinoma with brain metastasis - a case report. World J Surg Oncol (2012) 0.87
Pancreatic cystic neoplasms: Review of current knowledge, diagnostic challenges, and management options. J Carcinog (2015) 0.83
mAb Das-1 is specific for high-risk and malignant intraductal papillary mucinous neoplasm (IPMN). Gut (2013) 0.83
Brain metastasis in pancreatic cancer. Int J Mol Sci (2013) 0.82
Recurrence and Survival After Resection of Small Intraductal Papillary Mucinous Neoplasm-associated Carcinomas (≤20-mm Invasive Component): A Multi-institutional Analysis. Ann Surg (2016) 0.82
Invasive carcinoma derived from branch duct-type IPMN may be a more aggressive neoplasm than that derived from main duct-type IPMN. Oncol Lett (2013) 0.81
Intraductal papillary mucinous neoplasm of the pancreas: an update. Scientifica (Cairo) (2012) 0.81
The use of protein-based biomarkers for the diagnosis of cystic tumors of the pancreas. Int J Proteomics (2011) 0.80
GNAS mutation is a frequent event in pancreatic intraductal papillary mucinous neoplasms and associated adenocarcinomas. Virchows Arch (2015) 0.79
Management of Incidental Pancreatic Cystic Lesions. Viszeralmedizin (2015) 0.79
Role of pancreatic juice cytology in the preoperative management of intraductal papillary mucinous neoplasm of the pancreas in the era of international consensus guidelines 2012. World J Surg (2014) 0.78
Standardized terminology and nomenclature for pancreatobiliary cytology: The Papanicolaou Society of Cytopathology Guidelines. Cytojournal (2014) 0.78
[Precursor lesions of pancreatobiliary cancer]. Pathologe (2011) 0.78
Chondroitin sulfate proteoglycan CSPG4 as a novel hypoxia-sensitive marker in pancreatic tumors. PLoS One (2014) 0.78
Current roles of endoscopy in the management of intraductal papillary mucinous neoplasm of the pancreas. Dig Endosc (2015) 0.78
Cancer: Epithelial subtype influences the prognosis of invasive IPMN. Nat Rev Gastroenterol Hepatol (2011) 0.77
Cyst Features and Risk of Malignancy in Intraductal Papillary Mucinous Neoplasms of the Pancreas: Imaging and Pathology. Viszeralmedizin (2015) 0.77
Podoplanin expression in the cyst wall correlates with the progression of intraductal papillary mucinous neoplasm. Virchows Arch (2014) 0.76
Prognostic value of histological subtype in intraductal papillary mucinous neoplasm of the pancreas: A retrospective analysis of outcome from one single center. Medicine (Baltimore) (2017) 0.75
Intraductal Papillary Mucinous Adenocarcinoma of the Pancreas: Clinical Outcomes, Prognostic Factors, and the Role of Adjuvant Therapy. Viszeralmedizin (2015) 0.75
Loss of Trefoil Factor 2 From Pancreatic Duct Glands Promotes Formation of Intraductal Papillary Mucinous Neoplasms in Mice. Gastroenterology (2016) 0.75
Pancreatic resection for intraductal papillary mucinous neoplasm- a thirteen-year single center experience. BMC Cancer (2016) 0.75
Developmental Pathways Direct Pancreatic Cancer Initiation from Its Cellular Origin. Stem Cells Int (2015) 0.75
Natural History and Management of Intraductal Papillary Mucinous Neoplasms: Current Evidence. Viszeralmedizin (2015) 0.75
Diversity of Precursor Lesions For Pancreatic Cancer: The Genetics and Biology of Intraductal Papillary Mucinous Neoplasm. Clin Transl Gastroenterol (2017) 0.75
Pancreatic cancer from bench to bedside: molecular pathways and treatment options. Ann Transl Med (2016) 0.75
Molecular pathology of intraductal papillary mucinous neoplasms of the pancreas. World J Gastroenterol (2014) 0.75
Interobserver variability in intraductal papillary mucinous neoplasm subtypes and application of their mucin immunoprofiles. Mod Pathol (2016) 0.75
Post-brushing and fine-needle aspiration biopsy follow-up and treatment options for patients with pancreatobiliary lesions: The Papanicolaou Society of Cytopathology Guidelines. Cytojournal (2014) 0.75
Expansion of epigenetic alterations in EFEMP1 promoter predicts malignant formation in pancreatobiliary intraductal papillary mucinous neoplasms. J Cancer Res Clin Oncol (2016) 0.75
Endoscopic Management of Pancreatic Cysts. Dig Dis Sci (2017) 0.75
Natural History of Pancreatic Cysts. Dig Dis Sci (2017) 0.75
International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology (2006) 8.83
Intraductal papillary mucinous neoplasms of the pancreas: an updated experience. Ann Surg (2004) 5.12
Colorectal cancer in mice genetically deficient in the mucin Muc2. Science (2002) 5.08
Intraductal papillary mucinous neoplasms of the pancreas: an increasingly recognized clinicopathologic entity. Ann Surg (2001) 2.80
Classification of types of intraductal papillary-mucinous neoplasm of the pancreas: a consensus study. Virchows Arch (2005) 2.76
Study of recurrence after surgical resection of intraductal papillary mucinous neoplasm of the pancreas. Gastroenterology (2002) 2.76
Gene expression profiles in pancreatic intraepithelial neoplasia reflect the effects of Hedgehog signaling on pancreatic ductal epithelial cells. Cancer Res (2005) 2.64
Multicomponent analysis of the pancreatic adenocarcinoma progression model using a pancreatic intraepithelial neoplasia tissue microarray. Mod Pathol (2003) 2.63
Intraductal papillary mucinous neoplasms of the pancreas: an analysis of clinicopathologic features and outcome. Ann Surg (2004) 2.62
Intraductal papillary mucinous neoplasms of the pancreas: effect of invasion and pancreatic margin status on recurrence and survival. Ann Surg Oncol (2006) 2.12
Experience with 208 resections for intraductal papillary mucinous neoplasm of the pancreas. Arch Surg (2008) 2.04
Pathologically and biologically distinct types of epithelium in intraductal papillary mucinous neoplasms: delineation of an "intestinal" pathway of carcinogenesis in the pancreas. Am J Surg Pathol (2004) 1.96
Mucin-producing neoplasms of the pancreas: an analysis of distinguishing clinical and epidemiologic characteristics. Clin Gastroenterol Hepatol (2009) 1.90
Intraductal oncocytic papillary neoplasms of the pancreas. Am J Surg Pathol (1996) 1.82
Pancreatic duct glands are distinct ductal compartments that react to chronic injury and mediate Shh-induced metaplasia. Gastroenterology (2009) 1.78
Cystic neoplasm of the pancreas: a Japanese multiinstitutional study of intraductal papillary mucinous tumor and mucinous cystic tumor. Pancreas (2004) 1.76
The Cdx2 homeobox gene has a tumour suppressor function in the distal colon in addition to a homeotic role during gut development. Gut (2003) 1.70
Survival and prognosis of invasive intraductal papillary mucinous neoplasms of the pancreas: comparison with pancreatic ductal adenocarcinoma. Pancreas (2008) 1.67
Aberrant expression of MUC5AC and MUC6 gastric mucins and sialyl Tn antigen in intraepithelial neoplasms of the pancreas. Gastroenterology (2002) 1.64
Histopathologic basis for the favorable survival after resection of intraductal papillary mucinous neoplasm-associated invasive adenocarcinoma of the pancreas. Ann Surg (2010) 1.56
New classification of pancreatic intraductal papillary-mucinous tumour by mucin expression: its relationship with potential for malignancy. J Pathol (2002) 1.54
Intraductal papillary mucinous neoplasm (IPMN) of the pancreas: its histopathologic difference between 2 major types. Am J Surg Pathol (2006) 1.46
Colloid (mucinous noncystic) carcinoma of the pancreas. Am J Surg Pathol (2001) 1.40
The prognosis of intraductal papillary mucinous tumors of the pancreas. Hepatogastroenterology (2001) 1.37
Prognostic relevance of morphological types of intraductal papillary mucinous neoplasms of the pancreas. Gut (2010) 1.35
Pancreatic ductal adenocarcinomas with cystic features: neither rare nor uniform. Mod Pathol (2005) 1.32
Periostin deposition in the stroma of invasive and intraductal neoplasms of the pancreas. Mod Pathol (2008) 1.28
Peptide nucleic acid clamp PCR: a novel K-ras mutation detection assay for colorectal cancer micrometastases in lymph nodes. Int J Cancer (2004) 1.19
Preferential expression of MUC6 in oncocytic and pancreatobiliary types of intraductal papillary neoplasms highlights a pyloropancreatic pathway, distinct from the intestinal pathway, in pancreatic carcinogenesis. Am J Surg Pathol (2010) 1.19
Invasive cancer and survival of intraductal papillary mucinous tumors of the pancreas. Am J Gastroenterol (2002) 1.12
Characteristic clinicopathological features of the types of intraductal papillary-mucinous neoplasms of the pancreas. Pancreas (2007) 1.04
Development of pancreatic cancers during long-term follow-up of side-branch intraductal papillary mucinous neoplasms. Endoscopy (2010) 0.99
Invasive carcinoma originating in an intraductal papillary mucinous neoplasm of the pancreas: a clinicopathologic comparison with a common type of invasive ductal carcinoma. Pancreas (2006) 0.96
Intraductal papillary mucinous tumor of the pancreas. Gastrointest Endosc (2002) 0.95
Invasive intraductal papillary-mucinous neoplasm of the pancreas: comparison with pancreatic ductal adenocarcinoma. J Surg Oncol (2009) 0.94
Pancreatic mucinous noncystic (colloid) carcinomas and intraductal papillary mucinous carcinomas are usually microsatellite stable. Mod Pathol (2003) 0.93
Expression of Sonic hedgehog signaling pathway correlates with the tumorigenesis of intraductal papillary mucinous neoplasm of the pancreas. Oncol Rep (2008) 0.87
IgG4-related disease. N Engl J Med (2012) 15.76
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature (2012) 10.39
Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature (2003) 10.33
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med (2004) 9.80
Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med (2007) 9.04
Consensus statement on the pathology of IgG4-related disease. Mod Pathol (2012) 9.01
Long-term colorectal-cancer incidence and mortality after lower endoscopy. N Engl J Med (2013) 7.72
Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med (2012) 7.47
International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology (2012) 7.22
Aspirin use and survival after diagnosis of colorectal cancer. JAMA (2009) 6.93
Diagnosis of pancreatic cystic neoplasms: a report of the cooperative pancreatic cyst study. Gastroenterology (2004) 6.75
CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity. Nature (2008) 6.24
Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. Genome Res (2011) 5.97
Main-duct intraductal papillary mucinous neoplasms of the pancreas: clinical predictors of malignancy and long-term survival following resection. Ann Surg (2004) 5.09
Autoimmune pancreatitis. N Engl J Med (2006) 5.00
Incidental pancreatic cysts: clinicopathologic characteristics and comparison with symptomatic patients. Arch Surg (2003) 4.86
Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol (2009) 4.54
Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nat Genet (2013) 4.48
Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication. J Natl Cancer Inst (2013) 4.37
The SIRT1 deacetylase suppresses intestinal tumorigenesis and colon cancer growth. PLoS One (2008) 4.32
Recommendations for the nomenclature of IgG4-related disease and its individual organ system manifestations. Arthritis Rheum (2012) 4.27
Serrated lesions of the colorectum: review and recommendations from an expert panel. Am J Gastroenterol (2012) 4.22
Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol (2009) 4.17
Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet (2011) 3.92
Cystic neoplasms of the pancreas. N Engl J Med (2004) 3.89
Pancreatic ductal adenocarcinoma: long-term survival does not equal cure. Surgery (2012) 3.87
Genome-wide chromatin state transitions associated with developmental and environmental cues. Cell (2013) 3.83
Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J Clin Oncol (2005) 3.83
Aberrant overexpression of satellite repeats in pancreatic and other epithelial cancers. Science (2011) 3.77
Hepatic portal venous gas: the ABCs of management. Arch Surg (2009) 3.76
Fatty liver is associated with dyslipidemia and dysglycemia independent of visceral fat: the Framingham Heart Study. Hepatology (2010) 3.60
Clinical laboratory reports in molecular pathology. Arch Pathol Lab Med (2007) 3.55
Restriction of intestinal stem cell expansion and the regenerative response by YAP. Nature (2012) 3.54
mTORC1 in the Paneth cell niche couples intestinal stem-cell function to calorie intake. Nature (2012) 3.51
CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(-) and thereby promotes tumor growth. Cancer Cell (2011) 3.41
In vivo lineage tracing defines the role of acinar-to-ductal transdifferentiation in inflammatory ductal metaplasia. Gastroenterology (2007) 3.41
Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J Clin Oncol (2009) 3.39
Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma. J Clin Oncol (2006) 3.37
Recent measures to improve radiology reporting: perspectives from primary care physicians. J Am Coll Radiol (2012) 3.32
Pancreatic cyst fluid DNA analysis in evaluating pancreatic cysts: a report of the PANDA study. Gastrointest Endosc (2009) 3.32
Isolation and characterization of centroacinar/terminal ductal progenitor cells in adult mouse pancreas. Proc Natl Acad Sci U S A (2009) 3.25
Adult intestinal intussusception: CT appearances and identification of a causative lead point. Radiographics (2006) 3.22
Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. J Pathol (2014) 3.21
A novel somatic mouse model to survey tumorigenic potential applied to the Hedgehog pathway. Cancer Res (2006) 3.06
Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Oncologist (2011) 3.05
Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review. J Pathol (2010) 3.03
Branch-duct intraductal papillary mucinous neoplasms: observations in 145 patients who underwent resection. Gastroenterology (2007) 2.96
Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample. PLoS One (2008) 2.92
Case records of the Massachusetts General Hospital. Case 15-2006. A 46-year-old woman with sudden onset of abdominal distention. N Engl J Med (2006) 2.92
Rituximab therapy leads to rapid decline of serum IgG4 levels and prompt clinical improvement in IgG4-related systemic disease. Arthritis Rheum (2010) 2.90
Cancer classification using the Immunoscore: a worldwide task force. J Transl Med (2012) 2.88
Colorectal cancer: a tale of two sides or a continuum? Gut (2012) 2.85
Rituximab for the treatment of IgG4-related disease: lessons from 10 consecutive patients. Medicine (Baltimore) (2012) 2.84
PIK3CA mutation in colorectal cancer: relationship with genetic and epigenetic alterations. Neoplasia (2008) 2.82
Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. Ann Surg (2015) 2.79
Imaging-based quantification of hepatic fat: methods and clinical applications. Radiographics (2009) 2.79
Lymphocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpG island methylator phenotype. Clin Cancer Res (2009) 2.62
The impact of the 80-hour resident workweek on surgical residents and attending surgeons. Ann Surg (2006) 2.59
Pathology reporting of neuroendocrine tumors: application of the Delphic consensus process to the development of a minimum pathology data set. Am J Surg Pathol (2010) 2.56
A prospective cohort study shows unique epigenetic, genetic, and prognostic features of synchronous colorectal cancers. Gastroenterology (2009) 2.56
Long-term outcomes of autoimmune pancreatitis: a multicentre, international analysis. Gut (2012) 2.52
Prognostic role of PIK3CA mutation in colorectal cancer: cohort study and literature review. Clin Cancer Res (2012) 2.50
Hepatobiliary-specific MR contrast agents: role in imaging the liver and biliary tree. Radiographics (2009) 2.47
Intraepithelial lymphocytosis in architecturally preserved proximal small intestinal mucosa: an increasing diagnostic problem with a wide differential diagnosis. Arch Pathol Lab Med (2006) 2.46
EUS-guided FNA for the diagnosis of GI stromal cell tumors: sensitivity and cytologic yield. Gastrointest Endosc (2009) 2.45
Mucinous cystic neoplasm of the pancreas is not an aggressive entity: lessons from 163 resected patients. Ann Surg (2008) 2.45
A randomized trial comparing uncovered and partially covered self-expandable metal stents in the palliation of distal malignant biliary obstruction. Gastrointest Endosc (2010) 2.38
Pancreatic cysts 3 cm or smaller: how aggressive should treatment be? Radiology (2006) 2.35
Lifestyle factors and microsatellite instability in colorectal cancer: the evolving field of molecular pathological epidemiology. J Natl Cancer Inst (2010) 2.35
STAT3 plays a critical role in KRAS-induced pancreatic tumorigenesis. Cancer Res (2011) 2.35
Radiation dose reduction at multidetector CT with adaptive statistical iterative reconstruction for evaluation of urolithiasis: how low can we go? Radiology (2012) 2.35
Autoimmune pancreatitis: imaging features. Radiology (2004) 2.34
Whole-slide imaging digital pathology as a platform for teleconsultation: a pilot study using paired subspecialist correlations. Arch Pathol Lab Med (2009) 2.30
Association of CTNNB1 (beta-catenin) alterations, body mass index, and physical activity with survival in patients with colorectal cancer. JAMA (2011) 2.28
Serous cystadenoma of the pancreas: tumor growth rates and recommendations for treatment. Ann Surg (2005) 2.27